Российский кардиологический журнал

Расширенный поиск


Полный текст:


В статье представлены сведения об эффективности и безопасности длительного применения и возможностях использования дабигатрана для профилактики тромбоэмболических осложнений у пациентов с фибрилляцией предсердий. Рассматриваются критерии выбора оптимальной дозы дабигатрана.

Представлены данные последних зарубежных и отечественных рекомендаций
по использованию дабигатрана у пациентов с фибрилляцией предсердий.

Об авторах

Е. В. Сердечная
ГБОУ ВПО Северный государственный медицинский университет, Архангельск

д. м.н., профессор, зав. кафедрой поликлинической терапии и сестринского дела

С. В. Юрьева
ГБОУ ВПО Северный государственный медицинский университет, Архангельск

к. м.н., ассистент кафедры поликлинической терапии и сестринского дела

Б. А. Татарский
Федеральное государственное учреждение “Федеральный центр сердца, крови и эндокринологии имени В. А. Алмазова”, Санкт-Петербург, Россия

д. м.н., профессор, руководитель НКО “Нарушение ритма сердца”

Список литературы

1. Fuster V., Ryden L. E., Cannom D. S. et al. ACC/AHA/ECS 2006 guidelines for management of patients with atrial fibrillation– full text. A report of the American College of Cardiology/American Heart Assosiation Task Force on Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and Heart Rhythm Society. Europace 2006; 8:651–745.

2. Go A. S., Hylek E. M., Phillips K. A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370–5.

3. Wolf P. A., Abbott R. D., Kannel W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983–8.

4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med.1994; 154:1449–57.

5. A. John Camm, Gregory Y. H. Lip, Raffaele De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal 2012; 33:2719–47.

6. Diagnostic and treatment of arterial fibrillation. Guidelines VNOK and VNOA. Rational pharmacotherapy in Cardiology 2011, 4, suppl., 84p (Диагностика и лечение фибрилляции предсердий Рекомендации ВНОК и ВНОА 2011, Рациональная Фармакотерапия в Кардиологии 2011; 4: приложение, 84 c).

7. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 2009; 361:1139–51.

8. Gulseth M. P., Wittkowsky A. K., Fanikos J. et al. Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. Pharmacotherapy. 2011; 31:1232–49.

9. Blech S., Ebner T., Ludwig-Schwelliner E. et al. The Metabolism and disposition of oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386–99.

10. Stagier J., Rathgen K., Stahle H. et al. The Pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292–303.

11. Connoly S. J., Ezekowitz M. D. Yusuf S. et al. Newly identified events in the RE-LY trial N Eng J Med 2010;1010; 363:1875–6.

12. Boehringer Ingelheim Pharmaceuticals I. Press release: FDA approves pradaxa, making a major milestone to reduce the risk of stroke in patients with non-valvular atrial fibrillation 2010. (January 2012, date last accessed).

13. Medpage Today. Dabigatran: The Case of the Missing 110-mg dose.2010. (January 2012, date last accessed).

14. Medical News Today. PRADAX TM (dabigatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation 2010. (January 2012, date last accessed).

15. Diener H. C., Connoly S. J., Ezekowitz M. D. et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157–63.

16. Roskell N. S., Lip G. Y., Noack H. et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Tromb Haemost 2010; 104:1106–15.

17. QuarterWatch [Institute of Safe Medication Practices. ISMP Medication Safety Alert, January 12, 2012. Available at:

18. Wurster M. W. Dabigatran use in the real world: Preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Proceedings of the Thrombosis and Hemostasis summit of North America: Research abstracts. Am J Hematol 2012; 87: S146-S200.

19. Connolly S. J. Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the RELY-ABLE Double-blind Randomized Trial. CS.04. Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives. Presented on 7 November 2012 at the American Heart Association Scientific Sessions 2012.

20. Camm A. J., Kirchhoof P., Lip G. Y. et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ECS). Europace 2010; 12:1360–420.

21. Wann L. S., Curtis A. B., Ellenbogen K. A. et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123 (10):1144–50.

Для цитирования:


For citation:

Serdechnaya E.V., Yurieva S.V., Tatarskyi B.A. Reliability and safety of long-term dabigatran use in patients with atrial fibrillation. Russian Journal of Cardiology. 2013;(2):56-60. (In Russ.)

Просмотров: 209

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)